EconPapers    
Economics at your fingertips  
 

High Drug Prices, Big R&D Spenders and “Free Riders”: Canada in the Topsy Turvy World of Pharmaceuticals

Ake Blomqvist and Rosalie Wyonch
Additional contact information
Rosalie Wyonch: C.D. Howe Institute

C.D. Howe Institute Commentary, 2019, issue 535

Abstract: The main reason why health and general living standards in the world’s developed countries are so much better than in earlier eras is that today’s technology is much more advanced. But new technology does not come for free. Most of it, in healthcare and elsewhere, comes about because large amounts of resources are spent on R&D. All countries, especially those with high per-capita incomes, face an inevitable tension between their obligation to contribute their fair share to global pharmaceutical R&D financing and their desire to save money for the taxpayers, private insurers and patients who pay for drugs. In this Commentary, we compare how patent law and pharmaceutical regulation help determine drug prices in Canada, the US, and major countries in Europe and Australasia. Different countries respond in different ways to balancing the need to contain drug spending with contributing to the development of new pharmaceutical technologies that improve our ability to treat previously untreatable conditions. Government policy in many other countries plays a more comprehensive role than it does in Canada, either in the form of direct regulation of drug prices or via the government’s role, direct or indirect, in the process under which insurance plans negotiate with pharmaceutical companies about drug purchasing and pricing. Specifically, we examine what policies Canada should pursue to help overcome criticism that it is a free rider while avoiding paying more than its fair share. With complex interactions between regulations, patent laws, and R&D tax incentives and subsidies, it is difficult to determine whether Canada’s contributions to global pharmaceutical R&D are “optimal.” It is clear, however, that Canada is less of a free-rider than some other countries that employ restrictive drug pricing policies. Conversely, evidence suggests that US consumers pay more than their fair share towards pharmaceutical R&D due to high prices. Though lower than in the US, published prices of patented pharmaceuticals in Canada are comparable to or higher than in many other developed nations, as are our contributions to business R&D through direct funding and tax expenditures. We recommend that Canada pursue a two-track strategy. In the short run, we benefit from and, therefore, should aim for the lowest drug prices that we can get without inviting opposition from our main trading partners. But we should simultaneously work with our trading partners and international agencies toward a model of global R&D funding that overcomes the free-rider problem and moves us closer to a more efficient management of this aspect of the global commons.

Keywords: Health Policy; International Health Comparisons (search for similar items in EconPapers)
JEL-codes: I11 I13 (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
https://www.cdhowe.org/sites/default/files/attachm ... Comm%20535_final.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cdh:commen:535

Access Statistics for this article

More articles in C.D. Howe Institute Commentary from C.D. Howe Institute Contact information at EDIRC.
Bibliographic data for series maintained by Kristine Gray ().

 
Page updated 2020-09-13
Handle: RePEc:cdh:commen:535